TSX-V: AVCR OTCQB: AVCRF INVESTOR PRESENTATION 2019 Better Data, Better Health
WHO ARE WE? Avricore is a total health innovator capitalizing on technological advancements and consumer health trends, offering consumers, health providers and life- science companies the ability to take control of both spending and health outcomes. We intend on become the world’s largest health data company and are utilizing point-of-care technologies within community pharmacy to achieve this. www.avricorehealth.com
QUICK OVERVIEW ➤ Converted from VANC Pharmaceuticals, a generic drug maker with 91 generic offerings in 2018 to become Avricore Health Inc. ➤ We maintain the ownership of these dormant licences. ➤ Avricore is currently selling Hema-fer, an OTC iron supplement, to pharmacies across Canada. ➤ In the transition, Avricore purchased two technologies, the Avricore Platform (formerly Corozon Platform) and HealthTab. ➤ The Company’s primary focus today is on developing a network of point-of-care analyzers that utilizes its HealthTab software in community pharmacy.
W E L C O M E T O H E A LT H TA B A N D T H E R A S T R M O D E L Personalized Patient consent Reports De-identified Realtime Data The patient driven r apid a ccess, s afety t est r eporting system ( RASTR )
Turnkey System 2 panels , 21 results Lab-accurate analyzer Secure online results In-store kiosk
• Proven point-of-care screening system, designed to support pharmacists evolving role. • Empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. • Simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. • Results can be printed in-store or accessed securely online. • Watch short video here and visit our HealthTab website . •
R A S T R M O D E L • A network of HealthTab systems utilizing the Piccolo Analyzer in community pharmacies. • Running panels on consumers utilizing finger stick sample, monitoring up to 21 key bio-markers, and/or customizable tests. • Allows for API integration for better data flow and customization. • Provides harmonized, real-time data on consumer health. 1. The client purchases the drug or other health product. 2. The pharmacy leases the analyzers at a reasonable cost to become a part of the network. 3. The drug maker pays to access the network and sponsors test fees for consumer.
OUR TEAM Dr. Robert Sindelar - Director Bob Rai - CEO & director David Farnfield – Director BOARD DIRECTORS David Hall - Chairman & Director Alan Arnstein - Director Ray Chepsiuk – Board Advisor Mark Zhou – Board Advisor Sherif Guorgui - Board Advisor BOARD ADVISORS Philippe Ungat – Board Advisor David Huston - Board Advisor Kevin Strong - CFO Rodger Seccombe - Head of HealthTab Division MANAGEMENT Deena Siblock - Corporate Secretary Hector Bremner – EVP , Strategic Communications/Public Affairs For more information on our team, please visit our website
PROJECTIONS Annual Sales ('000 CAD) 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 - 2019 2020 2021 2022 2023 2024 2025 Annual Cash-Flow ('000 CAD) 12,000 10,000 8,000 6,000 4,000 2,000 - 2019 2020 2021 2022 2023 2024 2025 (2,000)
PROJECTIONS Our business model presents an exciting opportunity for investment. Cash flows and revenues are consistent with manageable expense loads. Equity 3,900 Investment CFs (before-tax) (3,900) - 1,117 7,453 9,539 9,791 10,509 10,688 10,688 10,688 10,688 (3,900) 1,096 5,933 7,432 7,404 7,992 8,120 8,096 8,086 8,081 CFs (after-tax) - Before tax 78% IRR 29,902 NPV After tax 68% IRR NPV 22,211
CAP STRUCTURE As at January 7, 2019 Includes shares issued to date as per the Lampyon agreement, the Healthtab Agreement, and the Corozon Agreement (please note: 681,818 of the Corozon shares are subject to a year hold, expiring on May 18, 2019). ** Does not include remaining shares to be issued pursuant to the Lampyon agreement, as these shares are based on calculating the volume weighed average closing share price on the last 5 trading days preceding the date of issue Common Shares Issued & Outstanding (per Computershare Report - 45,620,219 January 7, 2019) Reserved for Stock Options 2,566,072 Reserved for Warrants @ $0.20 - Expiry Jun 26, 2022 1,791,159 Reserved for Finders Warrants @ $0.20 - Expiry Jun 26, 2022 - All warrants - have been exercised. Reserved for Warrants @ $0.20 - Expiry Aug 3, 2022 742,667 Reserved for Warrants @ $0.20 - Expiry Nov 27, 2022 2,850,000 Reserved for Finders Warrants @ $0.20 - Expiry Nov 27, 2022 22,000 Reserved for Emerald Warrants @ $0.33 (Supply & Distribution Agreement) 3,030,303 - Expiry April 15, 2020 Reserved for Warrants @ $0.33 - Expiry Jul 31, 2020 5,327,335 Reserved for Finders Warrants @ $0.33 - Expiry Jul 31, 2020 88,800 TOTAL 62,038,555
OUR PARTNERS
JOIN US IN REALIZING THIS OPPORTUNITY Avricore Health is seeking to secure 40 Piccolo Xpress analyzers and expand the RASTR network in the immediate future. The company has no competition in this field, yet. However, as we have demonstrated here, the POCT market is rapidly growing as established health data methods get “smart.” To learn more about how you can invest in the growth of this technology, or partner with us to test your consumers, please contact us at: investor@avricorehealth.com
Recommend
More recommend
